Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Partial thromboplastin time" patented technology

The partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT or APTT) is a blood test that characterizes coagulation of the blood. A historical name for this measure is the kaolin-cephalin clotting time (KCCT), reflecting kaolin and cephalin as materials historically used in the test. Apart from detecting abnormalities in blood clotting, partial thromboplastin time is also used to monitor the treatment effect of heparin, a widely prescribed drug that reduces blood's tendency to clot.

Reagent for measuring activated partial thromboplastin time, method for producing same, reagent kit for measuring activated partial thromboplastin time, measurement method, sensitivity adjustment method, and activated partial thromboplastin time adjustment agent

PCT designated stageWO2026141607A1MedicinePartial prothrombin time
A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.
Owner:SEKISUI MEDICAL CO LTD

Eggshell membrane polypeptide with thrombin inhibition activity and application thereof

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Microfabricated device with micro-environment sensors for assaying coagulation in fluid samples

The present invention relates to sample analysis cartridges comprising micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, to performing coagulation assays using micro-environment sensors in a point of care sample analysis cartridge. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber configured to receive a biological sample, and a conduit fluidically connected to the inlet chamber and configured to receive the biological sample from the inlet chamber. The conduit may include a micro-environment prothrombin time (PT) sensor, and a micro-environment activated partial thromboplastin time (aPTT) sensor.
Owner:ABBOTT POINT OF CARE INC

Eggshell membrane polypeptide with thrombin inhibitory activity and application thereof

ActiveCN121895414BEGG SHELL MEMBRANEBiochemistry
The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Reagent composition, method for producing same, and inspection method

PCT designated stageWO2025197918A1Biological testingAntigenPlasma samples
Provided are: a reagent composition for measuring activated partial thromboplastin time, the reagent composition containing an antibody that binds to a blood coagulation factor as an antigen or an antigen-binding fragment thereof; and an inspection method including a step for mixing the reagent composition and a plasma specimen to be inspected at a prescribed ratio and measuring if the blood coagulation time thereof is T, and a step for determining that the plasma specimen is abnormal when the blood coagulation time T is longer than a designated reference.
Owner:SEKISUI MEDICAL CO LTD

Clinical auxiliary diagnosis model for microvascular invasion of hepatocellular carcinoma based on dictionary learning

The present invention provides a clinical auxiliary diagnosis model for microvascular invasion of hepatocellular carcinoma based on dictionary learning. The construction method includes: collecting medical imaging data and clinical statistical indicator data of patients after surgery for hepatocellular carcinoma; performing data annotation on the medical imaging data to obtain lesion regions of interest; performing feature selection on the lesion regions of interest to obtain optimal features; performing dictionary learning expression on the optimal features to obtain a sparse expression of the optimal features; and constructing a clinical auxiliary diagnosis model for microvascular invasion of hepatocellular carcinoma using a multivariate logistic regression algorithm based on the sparse expression of the optimal features and the clinical statistical indicator data, as well as the activated partial thromboplastin time. The present invention can solve the technical problem that there is no imaging omics-assisted diagnosis model specifically established for microvascular invasion of hepatocellular carcinoma in the prior art.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

An enhanced anti-coagulation antibacterial hemodialysis hollow fiber membrane and a method of making the same

PendingCN122441295AHemodialysisSpinning
The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.
Owner:ZHENGZHOU UNIV

Preparation method and application of deep sea blood coagulation factor XIa inhibitory peptide and composition thereof

The invention belongs to the technical field of biology, and particularly relates to a deep sea anticoagulant peptide, a composition thereof, a preparation method and application of the deep sea anticoagulant peptide in food, health food and medicine. The deep sea anticoagulant peptide is obtained by taking deep sea hippocampal clam as a raw material, crushing, carrying out enzymolysis by adopting pepsin, and carrying out freeze drying. The average molecular weight of the obtained peptide is less than 2000Da, and the peptide has excellent blood coagulation factor XIa inhibitory activity and antithrombotic effect. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is obtained through separation and purification by Sephadex G15 gel chromatography and Sepax GP-C18 reversed-phase chromatography and by utilizing an AlphaFold3-assisted virtual screening technology, and the IC50 of the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is 194.9 mu M. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE can be used for preparing the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE. An in-vitro anticoagulation experiment result shows that the peptide can remarkably prolong activated partial thromboplastin time (APTT) and has a remarkable anticoagulation effect. The anticoagulant peptide provided by the invention is derived from deep sea shellfish, is novel in sequence and low in molecular weight, can be used as a template molecule for further modification for research and development of peptide anticoagulant or antithrombotic drugs, and has a wide application prospect.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Deep sea anticoagulation peptide, preparation method thereof and application of deep sea anticoagulation peptide in anticoagulation products

The invention discloses an anticoagulant peptide derived from deep sea shellfish and an application of the anticoagulant peptide in antithrombosis. Through separation, purification and structural identification, three anticoagulant polypeptides are obtained from pepsase zymolyte of deep-sea Gigandas plasmos, and the amino acid sequences of the three anticoagulant polypeptides are respectively TVTRLSD, VSQPRSTL and VVTRVVR. The anticoagulant polypeptides have the advantages that the anticoagulant polypeptides are prepared from the pepsase zymolyte of the deep-sea Gigandas plasmos, and the anticoagulant polypeptides are prepared from the pepsase zymolyte of the deep-sea Gigandas plasmos; the method comprises the following steps: obtaining polypeptide KDETRTPEEL from protease K zymolyte of deep-sea metaphila palustris; the polypeptide YLERW is obtained from the protease K zymolyte of the deep sea hippocampus (Gigantidas hamaensis), and the polypeptide YLERW is obtained from the protease K zymolyte of the deep sea hippocampus (Gigantidas hamaensis). An in-vitro anticoagulation experiment result shows that the five deep sea polypeptides can remarkably prolong activated partial thromboplastin time (APTT) and show a remarkable anticoagulation effect. Wherein the inhibition activity on the blood coagulation factor Xa and thrombin is not obvious, and good selective inhibition characteristics are shown. The novel anticoagulant peptide with blood coagulation factor XIa selective inhibitory activity is separated and identified from deep sea shellfish resources, and a novel material basis and a technical approach are provided for prevention and treatment of thrombotic diseases and development of novel biological anticoagulant preparations.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI